A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

Key market opportunities for Cas12 proteins include rising government investments in biotech, increased demand for ...

BANDUNG, itb.ac.id - The PINTAR Diagnostics team from the School of Life Sciences and Technology (SLST), Institut Teknologi ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

However, regulatory hurdles and data standardisation remain key challenges. The global HOLMES CRISPR diagnostics market is ...

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...